Literature DB >> 26450007

Symptom-based management of the idiopathic interstitial pneumonia.

Brian T Garibaldi1, Sonye K Danoff2.   

Abstract

The term 'idiopathic interstitial pneumonia' (IIP) encompasses a wide variety of diseases with different and often unexplained pathophysiology as well as diverse natural histories. Unfortunately, many of these diseases are progressive and some are poorly responsive to available therapies. Despite the varied nature of IIPs, patients experience common symptoms related to their chronic lung disease. Dyspnoea, cough, fatigue and depression contribute substantially to morbidity and are often difficult to manage. The psychological stress of having a chronic and often life-limiting disease further complicates symptom control. Effective symptom-management requires a multidisciplinary approach that incorporates patient education and self-management to formulate goals of care and treatment plans. In this context, palliative care is incorporated from the time of diagnosis of an IIP and is not restricted to the end stages of the disease. Pulmonary rehabilitation plays a central role in symptom-management and has beneficial effects across multiple domains. In patients who do not respond to disease-specific treatments and are not candidates for lung transplant, early referral to hospice may improve quality of life for both patients and their families near the end of life.
© 2015 Asian Pacific Society of Respirology.

Entities:  

Keywords:  dyspnoea; interstitial lung disease; palliative care; pulmonary fibrosis; pulmonary rehabilitation

Mesh:

Year:  2015        PMID: 26450007     DOI: 10.1111/resp.12649

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  7 in total

Review 1.  Optimizing quality of life in patients with idiopathic pulmonary fibrosis.

Authors:  Mirjam J G van Manen; J J Miranda Geelhoed; Nelleke C Tak; Marlies S Wijsenbeek
Journal:  Ther Adv Respir Dis       Date:  2017-01-01       Impact factor: 4.031

2.  Original Research: ACE2 activator associated with physical exercise potentiates the reduction of pulmonary fibrosis.

Authors:  Luana O Prata; Carolina R Rodrigues; Jéssica M Martins; Paula C Vasconcelos; Fabrício Marcus S Oliveira; Anderson J Ferreira; Maria da Glória Rodrigues-Machado; Marcelo V Caliari
Journal:  Exp Biol Med (Maywood)       Date:  2016-08-21

Review 3.  Clinical manifestation, laboratory and radiology finding, treatment and outcomes of COVID-19: A systematic review and meta-analysis.

Authors:  Nahid Dehghan Nayeri; Javad Nadali; Anahita Divani; Mohammad Hasan Basirinezhad; Mohsen Meidani
Journal:  J Res Med Sci       Date:  2021-06-30       Impact factor: 1.852

4.  Nonpharmacological therapies for interstitial lung disease.

Authors:  Kathleen Oare Lindell
Journal:  Curr Pulmonol Rep       Date:  2018-10-18

5.  Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey.

Authors:  Catharina C Moor; Marlies S Wijsenbeek; Elisabetta Balestro; Davide Biondini; Benjamin Bondue; Vincent Cottin; Ron Flewett; Liam Galvin; Steve Jones; Maria Molina-Molina; Lurdes Planas-Cerezales; Antje Prasse; Helmut Prosch; Anne-Marie Russell; Michel Viegas; Guenther Wanke; Wim Wuyts; Michael Kreuter; Francesco Bonella
Journal:  ERJ Open Res       Date:  2019-10-21

6.  End-of-life home care of an interstitial pneumonia patient supported by high-flow nasal cannula therapy: A case report.

Authors:  Ken Goda; Tsuneaki Kenzaka; Kyosuke Kuriyama; Masahiko Hoshijima; Hozuka Akita
Journal:  World J Clin Cases       Date:  2020-10-26       Impact factor: 1.337

Review 7.  Palliative care in pulmonary medicine.

Authors:  Ellen Pierre de Oliveira; Pedro Medeiros Junior
Journal:  J Bras Pneumol       Date:  2020-07-06       Impact factor: 2.800

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.